Models of Research
The Thrombosis Research Institute (TRI) has been at the centre of the global understanding of thrombosis for several decades, producing the highest calibre research into the condition. We are uniquely positioned to lead the search for a definitive answer.
At TRI, the highest quality clinical research can be combined quickly with the latest academic research so innovations and the new treatments flow seamlessly from theory to practice.
TRI is a multi-disciplinary, independent organisation, uniquely positioned to enable scientists from many different disciplines (biochemists, haematologists, enzymologists, cell biologists and molecular geneticists) to work together as a coherent team thereby increasing the opportunity for cross fertilisation of ideas and the development of new research strategies. The Institute’s research programme also benefits from associations with hospitals in around 40 countries. These collaborations provide extensive clinical research facilities for investigating and treating a large number of patients as well as a unique opportunity for translational research.
This integrated philosophy encompasses the institute’s two main divisions:
Remarkably, TRI consistently exceeds all expectations of what an independent institute can offer, consistently producing genuinely world-leading research and driving through bold innovations. Breakthrough contributions already include development of the blood thinning agent heparin which saves 300,000 lives worldwide each year. Others include its demonstration of how commonly fatal clots occur post-surgery; how these discoveries lead to more effective forms of treatment; the role blood clotting plays in cancer, and how anti-clotting drugs may be of use in the care of cancer patients.
TRI’s current work involves identifying those at risk and protecting them, reducing further the number of preventable deaths in hospital; developing a vaccine for heart disease; establishing the world’s largest programme to understand and so improve management of the global burden of atrial fibrillation – a condition which increases the risk of stroke five times. TRI runs several thrombosis registries that advance the science of real-world data to strengthen the chain of evidence and extend quality research to under-represented countries, care settings and patients.
A new generation of drugs developed to target biomarkers – naturally occurring molecules or genes by which a particular pathology or physiology process or disease can be identified – currently being researched by TRI would represent a significant opportunity for interested parties. We follow a rigorous process of intellectual property protection so anything commercially realised will generate funds for contributors as well as brining enormous benefits to patients in the UK and around the world.
Click below to find out more about our current projects
The largest ongoing prospective atrial fibrillation (AF) registry with 57,262 patients recruited from 35 countries worldwide, providing insights on stroke prevention in AF and helping to develop strategies for improving patient outcomes.Click to read more
Prospective registry describing acute and long-term management and outcomes in 10,874 adult patients with venous thromboembolism (VTE), representative of everyday clinical practice in 28 countries.Click to read more
Prospective registry describing outcomes in over 5,000 adult patients with newly diagnosed AF who are treated with rivaroxaban.Click to read more
Prospective registry of VTE in 5,009 adults with newly diagnosed cancer of the breast, ovary, colon and rectum, pancreas, lung, or prostate, with up to 11 years of follow-up.CLICK TO READ MORE
Prospective study of biomarkers for thromboembolism in 100 patients with advanced breast cancer treated with chemotherapy.CLICK TO READ MORE
International survey of cancer-associated thrombosis, with responses from over 700 oncologists, haematologists, surgeons, thrombosis specialists, members of the palliative care team and specialist nurses from 54 countries.Click to read more
Randomised, phase III-b, Multi-centre, open-label, parallel study of Enoxaparin (low molecular weight heparin) given concomitantly with chemotherapy versus chemotherapy alone in patients with inoperable gastric and gastro-oesophageal cancer.
As current methods provide only partial protection against atherosclerosis, this important project is focused on developing a vaccine.
Sometimes referred to as ‘hardening of the arteries,’ atherosclerosis causes blood flow to become obstructed and may lead to coronary heart disease (CHD) or stroke. Atherosclerosis is widely recognised as a chronic inflammatory disease that involves innate ad adaptive immune responses.
Increasing evidence now suggests that some immune responses protect against its formulation while other accelerate the disease. This important paradigm shift in understanding has opened up the prospect of developing a cost effective vaccine which protects against atherosclerosis thereby significantly reducing the global burden of cardiovascular disease.
Research shows that vaccines have the potential of protecting against atherosclerosis by selectively activating protective immunity and by down-regulating disease-promoting immune responses and staff at the Thrombosis Research Institute have already made significant progress in developing a bifunctional antibody as a candidate for developing Atherovac®.
THIS HAS INVOLVED THE FOLLOWING PROCEDURE:
- Selection of the antigen chosen from several proteins and pathogens
- Immune response studies of selected antigens including proteins and peptides
- Engineering bifunctional antigens by introducing linger peptide antigens inoa dendoraspin scaffold
- Delivery vehicles for recombinant DNA vaccine
- Considerable attention is now being given to further develop these vaccines for human use and clinical testing
Biomarkers to identify risk of cardiovascular disease:
The purpose of this project is to develop a biomarker which can reliably and accurately predict the incidence of cardiovascular disease; (a biomarker is a tool that enables early detection of ‘high risk’ individuals thereby allowing prompt diagnosis and therapy assessment).
It is, currently, extremely difficult for medical staff to accurately evaluate even those patients who are showing early symptoms of the disease. This is because known markers are only released into the blood once irreversible damage has occurred.
Coronary heart disease (CHD), the most common form of cardiovascular disease, is a multifunctional disease with approximately 300 variables whose interaction depends on the risk of disease occurrence. Different biological systems are involved in CHD and their imbalance can either cause or accelerate the disease.
The advent of proteomics has revolutionised clinical research into this disease area. By allowing the simultaneous analysis of a large number of proteins and peptides, proteomic technologies now provide a real hope for early diagnosis and therapeutic response.
Using the most advance techniques, scientists at the Thrombosis Research Institute are working on identifying novel nano-peptides as biomarkers of CHD, as well as a number of lipid-associated inflammatory bio-markers.
PROJECTS CURRENTLY UNDERWAY INCLUDE THE FOLLOWING:
- The development of urine based assay for early diagnosis of CHD
- The role of lipid-associated inflammatory markers in Asian Indian families
- Identifying novel biomarkers for early diagnosis of CHD among Indian populations using surface Enhanced Laser Desorption Ionisation Time of Flight (SELDI – TOF)
- Oxidative stress and atherosclerosis: role of my myeperoxidase
- Evacuation of CMV genotype and estimation of viral load in subjects affected with CHD